Introduction
Inappropriate proliferative processes are the hallmark of the vascular pathologies of arteriosclerosis and essential hypertension (EHT) (Bevan, 1976; Ross, 1981; Owens and Reidy, t Corresponding author. ' Abbreviations: All, angiotensin 11; FCS, fetal calf serum; PDGF, platelet-derived growth factor; PDS, plasma-derived serum; SHR, spontaneously hypertensive rat; VSMC, vascular smooth muscle cell; WKY, Wistar Kyoto rat.
1985; Schwartz et al., 1986; Wissler, 1986) . One of the experimental models for investigation of these processes has made comparative use of the genetic strain of spontaneously hypertensive rats (SHR) and their normotensive Wistar Kyoto (WKY) littermates (Okamoto and Aoki, 1963) . Several laboratories have shown that vascular smooth muscle cells (VSMC) derived from SHR exhibit enhanced responsiveness to a number of growth factor and hormonal agonists, as well as to various levels of fetal calf serum (Folkow et al., 1973; Yamori et al., 1981; Haudenschild et al., 1985; Hadrava et aL, 1989; Scott-Burden etal., 1989a ,b,c,d, 1990 ). In comparative studies designed to elucidate the underlying causes of this differential responsiveness between SHR-and WKY-derived VSMC, we have assessed the ability of a number of agonists to stimulate S6-kinase activation and phosphoinositide metabolism in quiescent cultures of the different VSMC isolates Scott-Burden et al., 1989a,b,c,d ). Of particular interest was our observation that the response of SHR-VSMC to porcine platelet-derived growth factor (PDGF-BB) was similar to that of WKY-derived cells (Scott-Burden et al., 1989b,c) . In the light of data showing amplified responses of SHR-VSMC to all other agonists tested (Scott-Burden et 1989a,b,c,d; Hadrava et al., 1989; Resink et al., 1989a) , the response to PDGF was surprising since this mitogen is considered as the doyen of growth factors for vascular smooth muscle (Ross et al., 1978) .
Growth inhibition of VSMC by conditioned medium from cultured endothelial cells has been ascribed to the "shedding" of heparin/heparin sulfate (see Scott-Burden and Buhler, 1989 for review). We also demonstrated that SHR-derived cells exhibit a decreased susceptibility to growth inhibition by added exogenous heparinoids as a consequence of their decreased (as compared with WKY cells) number of cell-surface heparin binding-sites . This latter finding might imply that the increased in vivo growth of VSMC in hypertension reflects a reduced regulation of growth control by endothelial cell-derived heparinoids. However, neither the observation of inhibition of VSMC growth by endothelial cell conditioned medium nor a decreased sensitivity to inhibitory growth control can adequately explain our finding (Scott-Burden, unpublished data) that in coculture studies with VSMC and bovine aortic endothelial cells, and using mitogen-depleted medium, the proliferation of SHR-derived cells, but not WKY-VSMC, was stimulated. Factors relating to positive growth regulation need to be invoked.
Endothelial cells in culture synthesize a number of growth factors, including PDGF-BB and PDGF-AA and also secrete significant amounts of PDGF-AA (±0.5 ng.ml-1.24 h-1) into the conditioned medium (Fox and DiCorleto, 1986; DiCorleto and Fox, 1988) . Rat arterial smooth muscle cells cultured in serum-free (nonmitogenic) medium, have also been shown to express the gene for PDGF A chain (Naftilan et aL., 1989) . Secretion of the growth factor, however, was undetectable in stationary cultures (serum-free), but did occur in the presence of added exogenous PDGF or in proliferating cultures (containing serum) (Sjolund et aL., 1988) . Furthermore, stimulation of quiescent VSMC with angiotensin 11 (All) leads to the increased expression of the PDGF A chain gene. We have found that chronic, daily treatment with All of VSMC from SHR animals maintained in mitogen-depleted medium resulted in slow but sustained proliferation, whereas cells from WKY animals were only mildly stimulated under the same experimental conditions (Scott-Burden et aL., 1990) .
All these observations prompted our investigation of a possible differential responsiveness between SHR-and WKY-derived VSMC to the two homodimeric isoforms of PDGF, namely PDGF-AA and PDGF-BB. Our studies show that only the SHR-derived cells are sensitive to stimulation by PDGF-AA and that their sensitivity is a consequence of their expression of PDGF-a receptors.
Results
When quiescent cultures of VSMC from SHR and WKY rats were exposed to a number of growth factors or vasoactive peptides, we observed a significant differential activation of S6-kinase (Table 1 ) between the two cell types for all the agonists tested, with the exception of commercial preparations of human PDGF (predominantly PDGF-AB) and porcine PDGF (exclusively PDGF-BB). However, when similar experiments were performed using pure recombinant preparations of either PDGF-AA or PDGF-BB, a difference was observed ( Figure 1 ). Whereas the B chain homodimer stimulated S6-kinase to a similar extent in SHR-and WKY-VSMC, only SHR-VSMC were activated by PDGF-AA ( Figure 1 ). These differences were also seen after exposure of quiescent, myo[3H]-inositol-prelabeled cells to the two homodimeric PDGF isoforms. SHR-VSMC exhibited a stimulated phosphoinositide catabolic response to both mitogens, whereas only the B chain homodimer elicited this response in WKY-derived cells ( Figure 2 ). In dose-response studies for the homodimers, the concentrations of PDGF-BB eliciting a half-maximal increase in inositol phosphates in SHR-and WKY-VSMC were comparable (V0.8 ng/ml, Figure 3B ). For PDGF-AA the half-maximally effective concentration was -1.5 ng/ml for SHR-VSMC ( Figure 3A ) while, as shown in Figure 2 , the response of WKY-VSMC to this homodimer was negligible. Figure 4B ), supplementation of medium with PDGF-BB stimulated their proliferation to the same extent as SHR-VSMC. In the absence of added exogenous growth factor, SHR-VSMC gradually increased in cell number over the 10 d in culture ( Figure 4A ), whereas WKY-VSMC numbers were unchanged ( Figure 4B ). This finding supports the conclusion that SHR-VSMC were capable of conditioning their medium. Therefore, we tested whether the SHR-VSMC secreted a soluble factor into their medium. In two experiments ( Figure 4C ) VSMC were maintained for 10 d in medium containing 1% PDS either with or without medium changes every 2 d. For these experiments VSMC were seeded at a lower density than for growth studies presented in Figure 4 , A and B, to avoid possible exhaustion of medium nutrients during culture without medium changes. WKY-VSMC did not increase in cell number under either condition. However, the proliferation of SHR-VSMC in 10/o PDS was greater when cultured without regular medium changes, consistent with the accumulation of a secreted growth factor in the conditioned medium.
Recently it has been shown that the two PDGF receptor subunits, termed a and ,B, can dimerize to form three distinct high-affinity receptors (aa, ad, and ,3,B) with differing ligand specificity (a-subunit recognizes both, A-and B-chain, whereas the A-subunit recognizes only B-chain) . Furthermore, different cell types appear to express different relative and absolute numbers of these subunits and, consequently, respond differently to the three PDGF isoforms . We therefore examined whether the different responsiveness to PDGF-AA between VSMC from SHR and WKY rats might be due to a difference in their complement of surface a-receptor subunits. Saturation binding experiments with [1251]-labeled PDGF-AA and PDGF-BB indicate that SHR-derived VSMC express both a-and :3-subunits ( Figure   5 ). In contrast, WKY-VSMC exhibit a comparable complement of f-subunits, but virtually no asubunits ( Figure 5 ), which is similar to that previously observed for smooth muscle cells from umbilical cord vein . These findings were confirmed in competition binding studies with isolates of SHR and WKY cells prepared from animals obtained through a number of commercial suppliers (Table 2) . It should be noted that although the values for aand fl-receptor given in Table 2 were obtained by extrapolation and at a subsaturating ligand (Figure 6 ) by a monoclonal antibody raised against recombinant human PDGF-AA (pfa4), which does not recognize human or rat PDGF-BB but crossreacts with rat PDGF-AA (Hosang et al., 1990; in of PDGF-AA by cultured VSMC from human umbilical cord vein has previously been reported . To assess the role of endogenous PDGF-AA production and secretion in the autocrine growth exhibited by SHR-VSMC, we examined the ability of the pfa4 antibody to attenuate proliferation of SHR-VSMC (Figure 7 ). This anti-PDGF-AA antibody was without effect on VSMC growth for cultures maintained in lob PDS (Figure 7A) , but slightly decreased cell growth in the presence of 50/% fetal calf serum (FCS) (Figure 7B) , and completely inhibited the stimulation of cell proliferation due to exogenously added PDGF-AA.
Discussion
The importance of PDGF in the pathogenesis of vascular disease has been acknowledged since Ross and Glomset (1976) described its role in their "response to injury hypothesis." More recently, however, it has become evident that medial smooth muscle cells may be stimulated to proliferate and migrate in the absence of endothelial denudation (Poole and Florey, 1985; Reidy, 1985; Booth et al., 1989) , and this implies (Fox and DiCorleto, 1986; Walker et al., 1986; Majesky et al., 1988; Sarzani et al., 1989) .
VSMC from SHR exhibit many of the characteristics associated with smooth muscle cells cultured from atherosclerotic tissues (Schwartz et al., 1986) . One factor involved is PDGF (Chamley-Campbell et al., 1979; Sjolund et al., 1988) , and therefore its induction, e.g., by All (Naftilan et al., 1989) , may lead to the initiation of the vascular changes seen in atherosclerosis and hypertension. However, an enhanced synthesis of PDGF A chain homodimer can only influence this process if the VSMC also express specific cell surface receptors for the mitogen. This interrelationship between PDGF synthesis and receptor expression has been observed in vascular tissue during development (see Schwartz et al., 1986 for review). The differential (mitogenic) response of various cells of mesenchymal origin to the three PDGF isoforms is governed by the different (absolute and relative) levels of three distinct high-affinity PDGF receptors with different isoform-binding specificities present on these cells . Our data showing that VSMC from SHR both respond to PDGF-AA and express significant levels of a-receptor, whereas VSMC from WKY rats neither respond to PDGF-AA nor express detectable levels of areceptor, are in agreement with the above concepts.
The stimulation of proliferation of SHR cells which occurs in the presence of endothelial cells may reflect the response of these VSMC to the A chain-like PDGF produced by the endothelial cells (Fox and DiCorleto, 1986; DiCorleto and Fox, 1988; Libby et al., 1988) . The (Naftilan et al., 1989) and specific receptor genes. Furthermore, our finding that SHR-VSMC in culture also produce and secrete PDGF-AA, in addition to expressing the a-receptors, offers some explanation for the autocrine growth exhibited by these cells (Figure 4) . However, the presence of pfa4 during culture did not attenuate the proliferation of SHR-VSMC, even though in control experiments the anti-PDGF-AA antibody did inhibit the stimulation of growth by exogenous PDGF-AA (Figure 7) . Therefore, our data support that PDGF-AA is an important component in regulation of VSMC growth, but that the autocrine growth of SHR-VSMC cannot be explained merely by their secretion of PDGF-AA and its subsequent interaction with a-receptors present on the surface of these cells.
Some growth factors may regulate their own and/or other growth factor receptor expression (Deuel, 1987; Paulsson et al., 1987; Gronwald et al., 1989; Raines et al., 1989; Soma and Grotendorst, 1989) . Extracellular matrix components may also control VSMC growth (Majack et al., 1985; Penttinen et al., 1988; Scott-Burden and Buhler, 1989) . Thus, complex interactions (Penttinen et al., 1988) and which is clearly elevated in experimentally induced hypertension (Sarzani et al., 1989) , plays a role in the pathophysiology of human essential hypertension.
Materials and methods Materials
All tissue culture materials and chemicals were obtained from Gibco AG, Basel, Switzerland. Experimental animals (SHR/WKY rats) were originally from the inbred strains first described by Okamoto and Aoki (1963) Ross and Kariya (1980) . Growth experiments were performed with cells plated into 12 well multi-well plates in normal medium. Medium was replaced after 18 h with 1 /o PDS-medium and every 2 d thereafter with the same. Cell numbers were determined using a Coulter counter following trypsinization of cell layers as previously described (ScottBurden et a/., 1 989a). Cultures of Swiss 3T3-D4 fibroblasts were cultured and maintained as described by Hosang et a/. (1989) .
Phosphoinositide metabolism. Assays for activation of phospholipase C-mediated catabolism of phosphoinositides were performed on quiescent cultures of VSMC maintained in the presence of myo[3H]-inositol (2.5 ,uCi/ml) for 36 h before agonist stimulation exactly as described before Scott-Burden et al., 1989a) . The subsequent extraction and chromatographic (Dowex 1X4) resolution of inositol phosphates has also been described (Resink et al., 1 989a; Scott Burden et al., 1 989a) . S6-kinase activation and phosphorylation assays. The activation of protein synthesis (S6-kinase) in quiescent VSMC has been described previously 1 989a) . In every experiment the levels of activation obtained with 100/ FCS and serum-free medium were determined and used as positive and negative control values, respectively.
The levels of activation obtained with 1 0% FCS, as assessed by the ribosomal-subunit phosphorylation assay (Scott-Burden et al., 1 989a), were not significantly different between cells from SHR and WKY animals (see legend to Figure 1 ). Saturation and competitive binding assay. Saturation binding assays were performed on confluent cultures of quiescent VSMC at 4°C using [12511-labeled PDGF-AA or -BB homodimers as described previously . Specific binding was determined by the use of excess cold ligand and subtraction of the nonspecific value so obtained . For competition binding experiments VSMC were preincubated for 3 h at 40C in the absence or presence of either PDGF-AA (20 ng/ml) or PDGF-BB (20 ng/ml).
[1251]-PDGF-BB (2 ng/ml, -400 cpm/fmol) was added to all wells and incubations continued at 40C for 3 h. Reactions were terminated as described . Nonspecific binding (in wells preincubated with unlabeled PDGF-BB) was subtracted from all values. Specific ['251]-PDGF-BB bound to wells preincubated without additions or with unlabeled PDGF-AA represent binding to aand ,B-receptors or ,B-receptors, respectively (Siefert et al., 1989) . Binding to a-receptors was determined by subtraction of these values. Cultures of Swiss 3T3 fibroblasts were used as positive binding controls since these cells express receptors for all PDGF isoforms (a-and ,B-receptor) in culture (Gronwald et al., 1989; . PDGF levels in VSMC-conditioned media and immunoneutralization experiments. Rat VSMC were grown to confluency in DMEM plus 10%o FCS and then changed to MCDB medium without serum. After 24 h the medium was discarded, new MCDB medium was added, and collection continued for 2 wk with medium change twice weekly. Following a 10-to 20-fold concentration in an Amicon YM 10 membrane cell, the supernatants were analyzed in a competition binding assay using [1251]-PDGF-AA as the ligand and Swiss 3T3-D1 cells as assay cells . The concentrations of PDGF present in the supernatants (expressed as PDGF-AA-or -BB-equivalents) were calculated from standard curves constructed in parallel with known amounts of purified recombinant PDGF-AA and -BB, respectively. This binding assay does not discriminate between the three PDGF isoforms (all of them can fully compete with ['251 ]-PDGF-AA binding). Therefore, the supernatants were preincubated for 1 h at room temperature with monoclonal antibody pfa4 before adding them to the cells and performing a PDGF receptor binding assay. The pfa4 monoclonal antibody has been raised against recombinant human PDGF-AA and does not recognize human or rat PDGF-BB, but crossreacts with rat PDGF-AA (Hosang et al., 1990; in preparation) . This antibody (NC50 of 0.3 ng IgG/ml for PDGF-AA) showed <1%Yo crossreactivity against PDGF-BB and PDGF AB (NC50 of >30 ng IgG/ml).
Protein determination. Protein concentration was determined (Bradford, 1976 ) using bovine serum albumin as the standard.
